• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Long-term blood pressure measurement for evaluating the first dose response of captopril and ramipril in patients with a stimulated renin system].

作者信息

Lüders S, Schrader J, Schoel G, Ruschitzka F, Scheler F

机构信息

Abt. Nephrologie/Rheumatologie, Med. Universitätsklinik Göttingen.

出版信息

Z Kardiol. 1992;81 Suppl 2:41-4.

PMID:1387500
Abstract

First-dose-response of captopril 1 x 25 mg (no prodrug) and ramipril 1 x 2.5 mg (prodrug) were compared in two groups of 17 patients with moderate or severe hypertension and stimulated renin-angiotensin system (because of continuous diuretic therapy) by means of 24-h blood-pressure measurement at the 1st and 7th day of therapy. In the ramipril-group the antihypertensive effect started after 2 h, had its maximum (mean: -13/-8 mmHg) after 4 h and remained unchanged for 8 h. The antihypertensive effect was significant for 24 h. There was a slightly but not significant improved blood-pressure reduction at the 7th day compared to the 1st. The captopril-group showed a fast and marked decrease of blood pressure within the first hour, and reached its maximum (mean: -18/-10 mmHg) after 2 h. After 7 h there was no antihypertensive effect detectable. At the 7th day blood-pressure reduction was less pronounced compared to the 1st day. The results show that initial decrease of blood pressure in risk-patients is less severe with prodrug-ACE-inhibitors with slow onset of action so that counterregulation can be activated and prevent severe, fast, ACE-inhibitor-induced hypotension. 24-h-blood-pressure measurement is a sufficient method to evaluate first-dose-response of ACE-inhibitors.

摘要

相似文献

1
[Long-term blood pressure measurement for evaluating the first dose response of captopril and ramipril in patients with a stimulated renin system].
Z Kardiol. 1992;81 Suppl 2:41-4.
2
The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.肾素-血管紧张素系统与雷米普利,一种新型的转换酶抑制剂。
J Cardiovasc Pharmacol. 1989;14 Suppl 4:S46-52.
3
Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.血管紧张素转换酶抑制剂雷米普利对原发性高血压的体液及血压影响
Arzneimittelforschung. 1986 Nov;36(11):1693-6.
4
Ramipril: a review of the new ACE inhibitor.雷米普利:新型血管紧张素转换酶抑制剂综述
J Ark Med Soc. 1992 Feb;88(9):437-40.
5
Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.新型血管紧张素转换酶抑制剂雷米普利对原发性高血压患者血压昼夜变化的影响。
Am J Cardiol. 1987 Apr 24;59(10):86D-91D. doi: 10.1016/0002-9149(87)90060-9.
6
Dose-response relationship of ramipril in patients with mild-to-moderate hypertension.
J Cardiovasc Pharmacol. 1991;18 Suppl 2:S128-30.
7
Ambulatory 24-h blood pressure monitoring in essential hypertensives treated with the angiotensin-converting enzyme inhibitor ramipril.血管紧张素转换酶抑制剂雷米普利治疗原发性高血压患者的动态24小时血压监测
J Int Med Res. 1991 Jan-Feb;19(1):39-43. doi: 10.1177/030006059101900105.
8
Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.激肽释放酶-激肽系统和肾素-血管紧张素系统在原发性高血压患者中血管紧张素I转换酶抑制剂降压机制中的意义
Adv Exp Med Biol. 1989;247A:39-48. doi: 10.1007/978-1-4615-9543-4_7.
9
Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications.
Clin Physiol Biochem. 1990;8 Suppl 1:44-52.
10
Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
Am J Cardiol. 1987 Apr 24;59(10):104D-109D. doi: 10.1016/0002-9149(87)90063-4.